Exhibit 99.1
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023
-
- Small molecule TREM2 agonist IND submission and initiation of Phase 1 clinical trial on track for fourth quarter of 2023 -
- Appoints drug development veteran Christopher J. Silber, M.D. as Chief Medical Officer -
WATERTOWN, Mass., August 8, 2023 (GLOBE NEWSWIRE) Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage
biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2023, and provided an update on its recent progress.
During the quarter, we continued to advance our lead candidates for ALSP and Alzheimers Disease and are well-positioned to deliver on
multiple value-driving milestones in the second half of 2023, said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. Most notably, we are on track to provide interim data from IGNITE, our
ongoing Phase 2 trial evaluating VGL101 in people living with ALSP. This interim analysis will include the first six patients following six months of treatment. Together with data from our ongoing Natural History Study, ILLUMINATE, this analysis may
provide further observations relating to the trajectory of the disease and could be instrumental in validating key therapeutic biomarkers to support proof-of-concept of
VGL101.
In addition to VGL101, we have also made significant progress with our novel small molecule TREM2 agonist for the potential treatment
of Alzheimers Disease. We are on track to submit an IND application and initiate a Phase 1 clinical trial in healthy volunteers in the fourth quarter of 2023, concluded Dr. Magovčević-Liebisch. Driven by our mission
to bring transformative therapies to patients with both rare and common neurodegenerative diseases, we are thrilled by our continued progress advancing our pipeline.
Recent Highlights and Anticipated Milestones
VGL101, a monoclonal antibody TREM2 agonist
|
|
|
Added 40 mg/kg dose cohort in ongoing IGNITE Phase 2 clinical trial: IGNITE, the first-ever interventional
trial in people living with ALSP, is a global Phase 2, open-label clinical trial designed to evaluate the safety and tolerability of VGL101 in up to 15 patients with symptomatic ALSP who have a CSF1R gene mutation. The Company has added
a dose cohort in which patients will receive an intravenous (IV) infusion of VGL101 at 40 mg/kg approximately every four weeks, for a treatment duration of one year in addition to the initial dose cohort of 20 mg/kg. |
|
|
|
First interim data readout from 20 mg/kg cohort in ongoing IGNITE Phase 2 clinical trial expected in the
fourth quarter of 2023: The Phase 2 clinical trial evaluating VGL101 in people living with ALSP is ongoing and the Company remains on track to report interim data in the fourth quarter of 2023 from the first 6 patients at 6 months who
have received 20 mg/kg of VGL101. |
1